Oragenics has activated a second clinical site at Alfred Hospital for its Phase IIa trial of ONP-002, a drug candidate for treating concussion and mild traumatic brain injury (mTBI). The trial, already enrolling patients at Mackay Base Hospital in Australia, aims to enroll 40 patients to evaluate ONP-002's effectiveness in reducing brain inflammation and injury symptoms. This drug could become the first FDA-approved pharmacological treatment for concussion, addressing a significant unmet medical need. Data from this trial is expected by the end of 2026, supporting a planned Phase IIb trial in the U.S.
Following Shell's interim dividend payment for Q1 2026 on June 29, several senior executives, including CEO Wael Sawan and CFO Sinead Gorman, acquired shares through dividend reinvestment plans. These shares were obtained in respect of shares previou...
The global aliphatic hydrocarbon solvents and thinners market is projected to grow from $5.26 billion in 2026 to $6.81 billion by 2032, at a CAGR of 4.4%. Growth is fueled by rising demand in coatings, adhesives, and industrial maintenance, with mine...
The global data center semiconductor market is projected to grow from $86.8 billion in 2024 to $265.8 billion by 2029, driven by rising demand for AI-powered servers. The power stage segment will dominate due to its critical role in efficient power d...
The data center direct-to-chip cooling market is projected to grow from $3.33 billion in 2026 to $17.31 billion by 2032, at a CAGR of 26.5%. This growth is driven by the need for precise thermal management in advanced computing, especially for edge c...
The global environmental DNA (eDNA) market is projected to expand from $1.63 billion in 2026 to $5.61 billion by 2031, growing at a 10.2% CAGR. This growth is driven by advanced, non-invasive testing methods that detect species through genetic materi...
